Report from IPITA-TTS Opinion Leaders Meeting on the Future of β-Cell Replacement
- PMID: 26840096
- PMCID: PMC4741413
- DOI: 10.1097/TP.0000000000001055
Report from IPITA-TTS Opinion Leaders Meeting on the Future of β-Cell Replacement
Conflict of interest statement
Conflict of interest declarations for meeting participants: (1) Choudhary P: Medtronic Ltd. (clinical studies); Abbot Ltd. (2) Hering B: Novartis; Sanofi. (3) Korsgren O: TikoMed, Inc. (production of LMWDS); I Reg Medical (Production of Treg); I Cell Science (production of MSL). (4) O'Connell P: Novartis (local advisory); Jansen Silag (Local advisory); Astellas (Invited lecturer at educational symposia). (5) Odorico J: Regenerative Medical Solutions, Inc. (co-founder, chair, scientific advisory board). (6) Stabler C: University of South Florida (Webinar presenter); Converge Biotech (license technology, scientific advisor). (7) Weir G: Novo Nordisk (speaker); Novartis (speaker); Merck (speaker); Pfizer (consult).
Figures

References
-
- Kelly WD, Lillehei RC, Merkel FK, et al. Allotransplantation of the pancreas and duodenum along with the kidney in diabetic nephropathy. Surgery. 1967; 61: 827– 837. - PubMed
-
- The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993; 329: 977– 986. - PubMed
-
- Katz M, Laffel L. Mortality in type 1 diabetes in the current era: two steps forward, one step backward. JAMA. 2015; 313: 35– 36. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical